Results from Ph 2 IMGN853-0420 trial show ORR of 62.7% with ELAHERE + chemo followed by ELAHERE monotherapy in patients with ≥50% FRα-expressing PSOC April 15, 2026
CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer April 7, 2026
European Commission Approves KEYTRUDA + Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens April 7, 2026
Japan’s MHLW approves risovalisib (Risovalisib Mesilate Hydrate or Heitzexin) after chemo for ovarian clear cell carcinoma with advanced PIK3CA gene mutations March 31, 2026
Updated Ph 2 Data Showing Continued Improvement in Median OS with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer Reported March 31, 2026
FDA Fast Track designation granted to ZW191 for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC) March 31, 2026
FDA Approves Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer March 31, 2026
Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Ph 1b/2a Agent and Announces First Close of Seed Financing March 10, 2026
Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Ph 2 Results March 10, 2026
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission March 10, 2026
FDA places partial clinical hold on Ph 2 LINNET study of lorigerlimab in patients with gynecologic cancers March 3, 2026
OS Primary Endpoint Met in Ph 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer March 3, 2026
Randomized Ph 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer March 3, 2026
KEYTRUDA + Paclitaxel +/- Bevacizumab Significantly Improved OS vs Paclitaxel +/- Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer March 3, 2026
KEYTRUDA and KEYTRUDA QLEX, Plus Paclitaxel ± Bevacizumab, Approved for 2L/3L PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma February 17, 2026
Encouraging Patient Survival Observations Reported in Ovarian Cancer Lira-cel CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation February 17, 2026
Patient recruitment opened for Ph 1 trial of Innocell in patients with recurrent epithelial ovarian cancer February 9, 2026
Positive Results from Ph 1b/2 PESCO Trial of MVP-S, Keytruda and Cyclophosphamide in Recurrent Epithelial Ovarian Cancer (EOC) Reported February 1, 2026
Positive Results from Ph 1B/2 PESCO Trial of MVP-S with Keytruda and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC) Announced January 25, 2026
OS Primary Endpoint Met in Pivotal Ph 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer January 25, 2026
Sofetabart mipitecan receives US FDA Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer January 25, 2026
